Program
mocertatug rezetecan
Also written as “Mocertatug rezetecan”, “HS-20089” and “Mocertatug rezetecan (Mo-Rez)”.
In GlaxoSmithKline’s pipeline, ADC targeting B7-H4
. Its studies are mostly in Ovarian Neoplasms · Endometrial Neoplasms · Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 66 open or running | phase 3since Dec 12, 2025 | May 21, 2024 | Sep 22, 2027phase 1 · NCT06431594 |
| Hansoh Pharmaceutical Groupits history only | 55 open or running | phase 3since Feb 25, 2025 | Oct 29, 2021 | Mar 7, 2027phase 3 · NCT06855069 |
- Named in GlaxoSmithKline’s own pipeline as
mocertatug rezetecan GSK5733584
, phase 3, as of Sep 30, 2026 (source). - Named in Hansoh Pharmaceutical Group’s own pipeline as
HS-20089 (B7-H4 ADC)
, phase 3, as of Aug 26, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseGSK licensed it from Hansoh, for everywhere outside mainland China, Hong Kong, Macau and Taiwan.Announced Oct 20, 2023 · Source: GSK, Oct 20, 2023
History and studies of GlaxoSmithKline only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Oct 20, 2023GSK licensed it from HansohLicenseEverywhere outside mainland China, Hong Kong, Macau and Taiwan · announced · GSK
- May 21, 2024First study: phase 1 study in NeoplasmsFirst studyNCT06431594 · 675 planned · United States, Argentina, Australia and more
- Jul 10, 2025Named mocertatug rezetecanINNProposed as its International Nonproprietary Name in WHO's List 133 · before, HS-20089
- Dec 12, 20252 phase 3 studiesPhase 3 reachedNCT07286331, NCT07286266
- Jun 29, 20262 phase 3 studiesNCT07684612, NCT07684599
- Jul 1, 2026Phase 3 study in Ovarian NeoplasmsNCT07694427 · 720 planned · Argentina, Australia, Canada and more
- Oct 15, 2026Primary completion moved from 2029-12-17 to 2030-07-22Date moved laterphase 3 · +7 months · NCT07286266
Ahead
- Sep 22, 2027Primary completion: phase 1 study in NeoplasmsNCT06431594
- Feb 29, 2028Primary completion: phase 3 study in Endometrial NeoplasmsNCT07286331
- Jul 23, 2029Primary completion: phase 3 study in Endometrial NeoplasmsNCT07684599
- Sep 6, 2029Primary completion: phase 3 study in Ovarian NeoplasmsNCT07694427
TargetBeta
“ADC targeting B7-H4”the company's pipeline, read by Claude · source
“B7-H4 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of mocertatug, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) ”NCIt, by rule
Other programs on VTCN1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-B7-H4 Antibody Drug Conjugate BG-C9074rule | BeOne Medicines | phase 3 | 2 |
| puxitatug samrotecan | AstraZeneca | phase 3 | 2 |
| Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103rule | abl-bio-inc | phase 2 | 2 |
| Anti-B7-H4/MMAE ADC LNCB74rule | ligachem-biosciences-inc | phase 1 | 1 |
Studies
All 6 GlaxoSmithKline leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07694427Ovarian Neoplasms · Argentina, Australia, Canada and more | 3 | Recruiting | Sep 6, 2029 | 720 |
| NCT07684612Ovarian Neoplasms · Australia, Canada, Japan and more | 3 | Recruiting | May 21, 2030 | 690 |
| NCT07684599Endometrial Neoplasms · Canada, Japan, South Korea | 3 | Recruiting | Jul 23, 2029 | 610 |
| NCT07286331Endometrial Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Feb 29, 2028 | 600 |
| NCT07286266Ovarian Neoplasms · Australia, Canada, Japan and more | 3 | Recruiting | Jul 22, 2030 | 450 |
| NCT06431594Neoplasms · United States, Argentina, Australia and more | 1 | Recruiting | Sep 22, 2027 | 675 |
How it is read
Names in the registry
- “Mocertatug rezetecan”, 5 entries
- “HS-20089”, 2 entries
- “Mocertatug rezetecan (Mo-Rez)”, 1 entry
- “HS-20089+Bevacizumab”, 1 entry
- “HS-10502 + HS-20089”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 7 studies
- Endometrial Neoplasms, 2 studies
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.